Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.

Chen J, Shi C, Mahoney EM, Dunn ES, Rinfret S, Caro JJ, O'Brien J, El-Hadi W, Bhatt DL, Topol EJ, Cohen DJ.

Can J Cardiol. 2011 Mar-Apr;27(2):222-31. doi: 10.1016/j.cjca.2010.12.021.

PMID:
21459271
2.

Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.

Chen J, Bhatt DL, Dunn ES, Shi C, Caro JJ, Mahoney EM, Gabriel S, Jackson JD, Topol EJ, Cohen DJ.

Value Health. 2009 Sep;12(6):872-9. doi: 10.1111/j.1524-4733.2009.00529.x. Epub 2009 Mar 11.

PMID:
19490556
3.

Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

Bhatt DL, Topol EJ; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee.

Am Heart J. 2004 Aug;148(2):263-8.

PMID:
15308995
4.

Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).

Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, Fox KA, Montalescot G, Weber MA, Haffner SM, Dimas AP, Steg PG, Topol EJ; CHARISMA Investigators.

Am J Cardiol. 2009 May 15;103(10):1359-63. doi: 10.1016/j.amjcard.2009.01.342. Epub 2009 Apr 1.

PMID:
19427428
5.
7.

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators.

N Engl J Med. 2006 Apr 20;354(16):1706-17. Epub 2006 Mar 12.

8.

Interpreting the CHARISMA study. What is the role of dual antiplatelet therapy with clopidogrel and aspirin?

Bakhru MR, Bhatt DL.

Cleve Clin J Med. 2008 Apr;75(4):289-95. Review.

PMID:
18491435
9.

Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Sep 1;10(5):331-42. doi: 10.2165/11633970-000000000-00000.

PMID:
22853743
10.

A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.

Hsiao FY, Tsai YW, Huang WF, Wen YW, Chen PF, Chang PY, Kuo KN.

Clin Ther. 2009 Sep;31(9):2038-47. doi: 10.1016/j.clinthera.2009.09.005.

PMID:
19843493
11.

Combination antiplatelet agents for secondary prevention of ischemic stroke.

Vande Griend JP, Saseen JJ.

Pharmacotherapy. 2008 Oct;28(10):1233-42. doi: 10.1592/phco.28.10.1233. Review.

PMID:
18823219
12.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

13.

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.

Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(40):iii-iv, xv-xvi, 1-141. Review.

14.

Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial.

Hankey GJ, Hacke W, Easton JD, Johnston SC, Mas JL, Brennan DM, Bhatt DL, Fox KA, Topol EJ; CHARISMA Trial Investigators.

Stroke. 2010 Aug;41(8):1679-83. doi: 10.1161/STROKEAHA.110.586727. Epub 2010 Jul 1.

15.

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.

Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA; CHARISMA Investigators.

J Am Coll Cardiol. 2007 May 15;49(19):1982-8. Epub 2007 Apr 11.

16.

Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.

Helton TJ, Bavry AA, Kumbhani DJ, Duggal S, Roukoz H, Bhatt DL.

Am J Cardiovasc Drugs. 2007;7(4):289-97.

PMID:
17696569
17.

Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.

Hart RG, Bhatt DL, Hacke W, Fox KA, Hankey GJ, Berger PB, Hu T, Topol EJ; CHARISMA Investigators.

Cerebrovasc Dis. 2008;25(4):344-7. doi: 10.1159/000118380. Epub 2008 Feb 27.

PMID:
18303254
18.

High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial.

Weber M, Bhatt DL, Brennan DM, Hankey GJ, Steinhubl SR, Johnston SC, Montalescot G, Mak KH, Fox KA, Easton DJ, Topol EJ, Hamm CW; CHARISMA Investigators.

Heart. 2011 Apr;97(8):626-31. doi: 10.1136/hrt.2010.210419. Epub 2011 Mar 10.

PMID:
21393433
19.

Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.

Spinler SA.

Pharmacotherapy. 2009 Jul;29(7):812-21. doi: 10.1592/phco.29.7.812. Review.

PMID:
19558255
20.

Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.

Squizzato A, Keller T, Romualdi E, Middeldorp S.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD005158. doi: 10.1002/14651858.CD005158.pub3. Review.

PMID:
21249668
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk